Form 4: Amgen Director Mary E. Klotman Acquires 809 Shares Through RSU Grant

Amgen Inc. Director Mary E. Klotman has acquired 809 shares of common stock through a Restricted Stock Unit (RSU) grant, increasing her beneficial ownership to 1,528 shares.

Summary

• Mary E. Klotman, a Director of Amgen Inc. (AMGN), acquired 809 shares of common stock on May 23, 2025.
• The acquisition was a grant of Restricted Stock Units (RSUs) at a price of $0 per share, indicating a compensation-related award.
• These RSUs were granted under the Amgen Inc. 2009 Director Incentive Program, as amended, and the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
• The RSUs vested immediately upon grant.
• Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.
• Following this transaction, Mary E. Klotman beneficially owns a total of 1,528 shares of Amgen common stock.
• Directors have the option to defer payment of vested RSUs according to an elected deferral schedule.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates a routine, positive action (director acquiring shares) that aligns insider interests with shareholders, without any negative implications.

Positives

• The acquisition of shares by a director aligns their interests with those of the shareholders, indicating confidence in the company's future performance.
• The grant of Restricted Stock Units (RSUs) is a standard component of director compensation, reflecting established corporate governance practices.

Future Outlook

This document, a Form 4, primarily reports an insider transaction and does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Management Comments

• The transaction reflects the company's established compensation framework for its directors, as outlined in the Amgen Inc. 2009 Director Incentive Program and the Second Amended and Restated 2009 Equity Incentive Plan.

Industry Context

Insider transactions, particularly the grant of equity awards like Restricted Stock Units (RSUs) to directors, are a common practice across publicly traded companies in the biotechnology and pharmaceutical industry. These grants serve to compensate directors for their service and align their financial interests with the long-term performance of the company, a standard approach to corporate governance and executive compensation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to directors is a widely adopted compensation practice among large-cap pharmaceutical and biotechnology companies, such as Pfizer, Johnson & Johnson, and Merck, which typically use equity-based awards to incentivize and retain board members.
• The immediate vesting of RSUs for directors, as seen with Amgen, is also common, though some companies may have staggered vesting schedules or performance-based conditions.
• The use of a formal Director Incentive Program and Equity Incentive Plan, like Amgen's 2009 plans, is standard for establishing transparent and compliant compensation structures, comparable to those at companies like Gilead Sciences or Bristol Myers Squibb.

Corporate Governance

Related Party Transactions

• The acquisition of 809 shares by Director Mary E. Klotman through an RSU grant is a related party transaction, as it involves a transaction between the company and a member of its board of directors, executed under a pre-approved incentive program.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests with those of the shareholders, potentially fostering better long-term decision-making.
• Employees: No direct impact on employees is indicated by this specific filing, though the underlying equity plan may also apply to employees.

Next Steps

• Mary E. Klotman may elect to defer the payment of the vested RSUs according to an elected deferral schedule.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Incentive Plan, Stock Grant